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Adolescents diagnosed with and treated for cancer represent a particular vulnerable patient
population with unique and complex medical and psychosocial needs that extend beyond the
completion of treatment (1–4). These cancer patients are in the most critical phases of their
development (5–7), with brain, body, mind, and social environment in constant transformation
conferring vulnerability to some individuals and resilience to others. Adolescence is characterized
by a heightened incidence (and first onset) of various mental illnesses (8–10). Cancer during
adolescence influences peer relationships, changes mood and behavior, interferes with cognitive
functioning, educational achievement, and increases the risk for the onset of psychopathology (11,
12). Furthermore, treatment is often accompanied by numerous physical and psychological
symptoms such as nausea, vomiting, sleep disturbance, fatigue, pain, changes in body weight and
body-image (2), treatment-induced psychosis, depression, and anxiety. Importantly, peer
interactions in young cancer patients is often suddenly interrupted putting them at a higher risk
for the development of emotional and behavioral problems. Even though many of these concerns
remain largely unattended because of a lack of timely detection and management (13, 14), recent
data indicate a growing awareness of the specific needs of this patient population suggesting that a
concerted effort should be made to develop age-appropriate resources that could help them manage
their illness and its treatment (15).
When asked, adolescents indicate five domains of concern: 1) physical, emotional, behavioral,
and mood problems related to treatment; 2) psychosocial issues; 3) present and future adjustments
once the therapy has finished; 4) transition, organization, and management of survivorship; and
5) need to be better connected, involved, and informed (16–20).
Given this, it is vital to capture, as early as possible, the biological, psychological, emotional,
behavioral, and social modifications in young cancer patients to expand our day-to-day
understanding of the factors affecting their vulnerability.June 2021 | Volume 11 | Article 6735811
Blom et al. Digital Approach to Adolescent Behavioural ToxicityMost importantly, reviews and guidelines based on best
practice stress the fact that cancer in adolescents does not
always have chronic negative outcome especially if we
understand which individuals are at heightened risk (20). Any
issue in the five domains of concern listed above must be
detected early to put timely and preventive measures into place
(21). Adolescent cancer patients represent an enormously
heterogenous group and while most somatic treatments are
accompanied by the development of acute or chronic
unwanted effects (2, 4), we currently lack the capacity to
distinguish individual trajectories leading to increased
vulnerability or resilience. A paradigm shift is essential to
detect the distinct clinical pathways of high-risk individuals
(22–24).
Current innovative digital approaches to patient care and
monitoring offer a unique opportunity to create predictive
models of individual vulnerability based on the integration and
interdependencies of diverse sources of information. The
analysis of the data contained in these platforms allow the
projection of potential outcomes and disease trajectories,
identifying those patients that are progressing from generic
vulnerability to becoming at high risk for a negative event.
Digital tools may have numerous potential benefits compared
to traditional assessments: they are non-invasive, ecological, do
not demand extra efforts, and provide continuous access which
offers timely understandings of the emotional, behavioral,
cognitive, and treatment related changes. Also, while not all
studies underline a clear benefit, some of them indicate that they
are unrestricted by time and place, and offer immediate access to
data and intermediate endpoints, reduce stressful visits,
remove barriers to access to care (fear, isolation), stimulate
patient empowerment, and, most importantly, help in the
identification of high-risk patients and their risk stratification
(23–26). As a result, the integration of various digital tools in a
“toolbox,” would offer a concrete opportunity to modify, replace,
or accompany the current more categorical approach and shift to
a multimodal dimensional methodology (27, 28) in which
evidence is gathered from different domains, ranging from
subtle neurocognitive disfunction (29–33) to biomarkers.
Ultimately, the multidimensional continuous recording of data
and especially their dynamic relationships would become an
integral part of the care plan and serve as specifiers of an high-
risk status (34, 35).A DIGITAL APPROACH IN
UNDERSTANDING ACUTE AND
CHRONIC BEHAVIORAL TOXICITY IN
ADOLESCENTS TREATED FOR CANCER
Progress in the use of digital technologies and data analytics have
created unmatched prospects to evaluate and alter health
behavior and outcomes. Young adults and adolescents display
a high compliance with the digital world surrounding them and
are very comfortable with modern technologies (36, 37).
However, while acceptance of digital tools is high (19), manyFrontiers in Oncology | www.frontiersin.org 2health applications and tools are not specific for adolescents.
Apps for various pathological conditions exist, supporting the
life of patients suffering from diabetes, obesity, hypertension, and
psychopathology (38). Several apps, mostly focused on symptom
tracking and monitoring quality of life, exist for adult cancer
patients while very few have been developed with the adolescent
patient in mind (25, 39–44).DIGITAL PHENOTYPING AS PART OF A
DIGITAL TOOLBOX
Adolescents with cancer consider psychological, emotional,
cognitive, and social problems, issues of major concern (11–
13). Touching the right cords is fundamental if we want to
protect and help them. Digital phenotyping offers promising
features for use in this patient group because it may allow
objective and continuous measurements, documenting, and
quantifying mood, energy level, and cognition in a non-
invasive manner using personal digital devices (such as
smartphones or wearables). This ecological approach centered
on patients’ everyday lives has proven valuable when assessing
symptomatology. Analysis by real-time algorithms allows for
checking and detecting alarming pattern changes in daily
functioning and predict when an individual shifts from being
at risk to a patient that is about to experience an episode in need
of immediate care (32, 33). Thus, digital phenotyping provides a
period of long continuous surveillance of disease related
moderators and mediators elucidating the temporal dynamics
between specific biological mechanisms and changes in mood
and behaviors.
Digital phenotyping, however, should be taken as just one of
the instruments of a digital health toolbox. If we want a
comprehensive approach, digital phenotyping must be
accompanied by other participatory and communication tools,
which include various objective biological markers that can be
detected by sensors, wearables, and devices, such as
smartwatches, rings, and fitness trackers (38, 45–47). Digital
biomarkers and dynamic monitoring of functions, such as
heartbeat, weight, blood pressure, temperature, sleep patterns,
fatigue, and pain, provide important additional parameters
related to disease, treatment related side effects, and
effectiveness of treatment.
Lastly, the toolbox should also include the use of subjective
measures, such as patient reported outcomes since they capture
different nonobjective aspects of the same clinical construct, for
instance fatigue (22, 25, 44). This information requires the active
participation of the individual including symptom reporting or
the use of activity diaries tracking personal impressions and
perceptions, or responding to periodic questionnaires related to
personal wellbeing and psychosocial health. A final advantage of
an integrated digital approach is putting the adolescents at the
very center of the data generation to fulfill their much-felt need
to be informed, educated, and connected (20). In addition,
providing access to information, videos, tutorials offering
access to support groups or patient advocacy organizations (if
desired) will connect and empower them even more.June 2021 | Volume 11 | Article 673581
Blom et al. Digital Approach to Adolescent Behavioural ToxicityDigital phenotypes, digital biomarkers, mobile asynchronous
questionnaires, and self-reports provide data along various
dimensions that, once collected, will reflect the complexity and
delicacy of the behaviors of adolescent patients. Challenges also exist
with this approach since to benefit from a digital analysis, very large
amount of data reflecting the complexity of developmental and
disease related factors that may alter individual behavior almost
instantly must be factored in (Figure 1).DYNAMIC MAPPING OF
MULTIDIMENSIONAL DATA
At present, evidence has accumulated that the engrained
traditional approach linking just one or a few (often molecular
or biological) mediators to an illness related phenotype, limits
the understanding of the complex underlying pathologic
conditions which has hampered progress in the development
of efficient treatments.
To this end, traditional statistical approaches are not capable
of capturing the particularity of each individual specific
phenotype. At present, modern approaches coming from
machine learning, especially those related to deep learning,
provide innovative ways to tackle the complexities of
multidimensional continuous data collection. The integrationFrontiers in Oncology | www.frontiersin.org 3of data collected from the different instruments in a digital
toolbox, ranging from sensor recorded physical functioning to
digital phenotyping, need a more sophisticated approach, such as
deep learning and network analysis. Recently, researchers have
started to use deep neural networks in big-data rich areas such as
online social media platforms or smartphone and mobile sensor-
based data relating them to mental health (48–51).
Therefore, combining network science and dynamic system
theory with a toolbox containing digital phenotyping and
biomarkers permits the integration of data across diverse levels of
analysis and capture the nature of their dynamic relationship over
time, both for patients and treatment modalities (52–57) (Figure 1).
New conceptual thinking may result in increasingly
explanatory and predictive models resulting in a more realistic
image of the strengths and vulnerabilities of these young patients
at high-risk for behavioral and emotional problems. Network
analysis helps to determine if one domain or function is more
important than others, if changes in one domain, factor, or
symptom dynamically influence the function of others, and
finally, what factor or domain is driving the network. In sum,
network analysis will not only indicate which domains and
factors mostly define individual vulnerability but will have
important implications for clinical practice motivating
personalized strategies in the prevention of mood, behavioral,
and cognitive problems (46, 54–57).A B C D
FIGURE 1 | An integrated multi-dimensional model for the use of digital phenotyping as part of a digital “toolbox” to be used in adolescents with cancer. Our
hypothetical model is defined over four phases: (A) The data collection phase: In green: Objective continuous non-invasive data collection related to mood, behavior,
cognition, and use of social media (using a digital phenotyping app); in blue: Objective continuous non-invasive collection of biomarkers from sensors and wearables
(heartrate, blood pressure, temperature); in purple: Periodic collection of subjective perceptions and impressions related to mental and physical wellbeing (e.g.,
diaries, self-reports, and questionnaires) and type of treatment, protocol, and protocol phase; (B) The data transformation phase, that is, the conversion of raw data
into usable algorithms and outputs to feed data analysis and network construction; (C) Creation of individual networks based on data from different dimensions and
domains to understand the strengths and needs of each patient. The circles represent signs, symptoms, and factors related to the domains of data collection (green,
blue, and purple). The red lines represent the connections among signs, symptoms, and factors; (D) Development of dynamic networks to monitor change over time
in network organization and connectivity aimed at identifying windows of vulnerability and resilience. Letters and colors refer to those shown in the figure.June 2021 | Volume 11 | Article 673581
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INEVITABLE CHALLENGES
Notwithstanding the promise to deliver a revolution in the health
care of children and especially adolescents diagnosed with
cancer, the incredible potential of the digital era comes with
substantial questions regarding its implementation.
While artificial intelligence, deep learning, and network analyses
sustain the analysis of complex data, their use requires the
acquisition of innovative expertise and competence. The analysis
of large multi-domain data bases needs a multidisciplinary
collaborative effort which is currently lacking.
Today, more than in the past we are witnessing an increasing
number of disruptive products such as advancedmRNA, gene and
cell therapies that face unexpected legal and ethical challenges.
Therefore, data must be managed in a thoughtful way. We must
prepare for a profound change in the way data are gathered and
integrated from multiple sources including digital tools. For
digitally captured data, quality measures must be incorporated,
and the sensitivity, specificity, accuracy, and precision of device
parameters and measurements need to be tested.
Also, personal health-related data, especially from minors,
should be considered in a meaningful way. If we want to engage
young patients as data generators, a trusted ethical, legal, and
regulatory ecosystem should be created with clear rules.
Innovative, legal, organizational, and technical solutions are
needed to share their sensitive, health-related personal data in
an ethical and privacy-compliant environment.
Therefore, adopting this novel approach should be accompanied
by adequate ethical and regulatory support to fully protect the
patient and to overcome present and future challenges linked to
confidentiality and accountability. While having the knowledge and
the technical capacity to truly benefit from digital tools, widespread
information, education, and training would be needed from both
the clinician and the patient. Thus, we, adults, clinicians, and
researchers need to step up to the challenge and avoid becoming
the rate limiting step in embracing a new era (23, 24).POSSIBLE IMPACT
The impact of digital phenotyping and dynamic monitoring likely
involves multiple domains of care as well as multiple stakeholders.
Researchers will have to find new ways to enrich, share, and analyze
data and develop strategies to support patient friendly access. At
the same time research should direct efforts to the development of
decision-making paradigms that better inform and sustain clinical
interventions. For patients, the use of a digital toolbox represents an
innovative way to study their needs and challenges while being
treated for cancer. With the patient as active participants we will be
better able to transform their needs into interventions that aim to
support their wellbeing and prevent serious problems before they
start. Fine-grained phenotypes representing the individual aspects
of emerging problems may induce industry to develop new
therapies and sustain faster progress from bench to bedside.
Finally, an ecological day-to-day collection of data shouldFrontiers in Oncology | www.frontiersin.org 4stimulate regulators to identify new targets and determine when
and how a target may become acceptable for regulatory decision
making centered on the adolescent.WITH THE FUTURE OF THE
ADOLESCENT PATIENT IN MIND
The care process surrounding the adolescent patients is an
active, planned, coordinated, comprehensive, multidisciplinary,
and multi-stakeholder process that should be flexible,
developmentally appropriate considering the interaction and
interdependency of medical, psychosocial, behavioral, and
environmental factors. The use a digital toolbox combined
with network analysis may define developmental trajectories of
risk and resilience and reveal more fine-grained cognitive and
behavioral phenotypes, that together with clinical factors, and
biological markers, may explain the relationship between disease,
age specific risk, and the efficacy of treatment. To achieve this,
the combination of sufficiently diverse tools, by themselves not
new, will feed complex datasets with broad as well as deep
phenotypic representation of the patients’ needs.THE ADDED VALUE OF ENTERING THE
DIGITAL ERA
According to the suggested paradigm shift, each individual
young patient will be involved in a process aimed to predict,
prevent, and personalize their care, stressing the individual’s
participation moving from a passive receiver of care to an active
and conscious contributor to their wellbeing.
A “digital toolbox” which includes digital phenotyping will
give us hope for the future (58) and will help to enrich the care of
adolescent patients with cancer. Starting from each individual
patient, and within known treatment modalities and protocols,
we will be better able to recognize interrelated behaviors, risk
factors, and treatment and disease related side effects and to
isolate the domain(s) most central to possible adverse outcome.
Combining pharmacovigilance and behavioral phenotyping with
easily accessible technologies and the most innovative analyses
will improve timely access to the detection of adverse medical and
behavioral events. In turn, this will stimulate efforts to improve,
develop, and implement innovative programs of personalized
interventions adapted to the clinical needs and characteristics of
individual patients. Finally, such a process, would fully respect the
so-called P4 of Precision Medicine: predictive, preventive,
personalized, and participatory, putting the adolescent patient
at the very core of their present and future health.AUTHOR CONTRIBUTIONS
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